Regulation of mammalian target of rapamycin complex 1 by Bcl-2 and Bcl-XL proteins

Journal of Biological Chemistry

Volumn 288, Issue 40, 2013, Pages 28824-28830

  Zou, Huafei ^a   Lai, Yumei ^a   Zhao, Xuwen ^b   Yan, Gonghong ^a   Ma, Dongzhu ^a   Cardenes, Nayra ^a   Shiva, Sruti ^a   Liu, Yongjian ^a   Bai, Xiaochun ^b   Jiang, Yong ^b   Jiang, Yu ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEINS; CANCER DEVELOPMENT; COMPLEX 1; EXPRESSION LEVELS; MAMMALIAN TARGET; PROTEIN KINASE; SIGNALING ACTIVITY;

BIOCHEMISTRY; BIOLOGY;

PROTEINS;

FK 506 BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN BCL 2; PROTEIN BCL XL;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BCL-2; BCL-XL; FKBP38; MITOCHONDRIA; MTOR COMPLEX (MTORC); MTORC1; S6 KINASE; SIGNALING;

APOPTOSIS; BCL-X PROTEIN; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HEK293 CELLS; HELA CELLS; HUMANS; MITOCHONDRIA; MULTIPROTEIN COMPLEXES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BINDING; PROTEIN TRANSPORT; TACROLIMUS BINDING PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84885133930     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.505370     Document Type: Article

References (20)

1. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
2. Youle, R. J., and Strasser, A. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59
3. Kelly, P. N., and Strasser, A. (2011) The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18, 1414-1424
4. Shirane, M., and Nakayama, K. I. (2003) Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat. Cell Biol. 5, 28-37
5. Ma, D., Bai, X., Zou, H., Lai, Y., and Jiang, Y. (2010) Rheb GTPase controls apoptosis by regulating interaction of FKBP38 with Bcl-2 and Bcl-XL. J. Biol. Chem. 285, 8621-8627
6. Bai, X., Ma, D., Liu, A., Shen, X., Wang, Q. J., Liu, Y., and Jiang, Y. (2007) Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318, 977-980
7. Laplante, M., and Sabatini, D. M. (2012) mTOR signaling in growth control and disease. Cell 149, 274-293
8. Ma, X. M., and Blenis, J. (2009) Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307-318
9. Oh, W. J., and Jacinto, E. (2011)mTORcomplex 2 signaling and functions. Cell Cycle 10, 2305-2316
10. Bai, X., and Jiang, Y. (2010) Key factors inmTORregulation. Cell. Mol. Life Sci. 67, 239-253
11. Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., and Vogelstein, B. (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290, 989-992
12. Fiebig, A. A., Zhu, W., Hollerbach, C., Leber, B., and Andrews, D. W. (2006) Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 6, 213
13. Dai, Y., Rahmani, M., Corey, S. J., Dent, P., and Grant, S. (2004)ABcr/Ablindependent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. 279, 34227-34239
14. Jiang, M., and Milner, J. (2003) Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev. 17, 832-837
15. Tran, N. L., McDonough, W. S., Savitch, B. A., Sawyer, T. F., Winkles, J. A., and Berens, M. E. (2005) The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFB pathway activation and BCL-XL/BCL-W expression. J. Biol. Chem. 280, 3483-3492
16. Uhlmann, E. J., Subramanian, T., Vater, C. A., Lutz, R., and Chinnadurai, G. (1998) A potent cell death activity associated with transient high level expression of BCL-2. J. Biol. Chem. 273, 17926-17932
17. Wang, N. S., Unkila, M. T., Reineks, E. Z., and Distelhorst, C. W. (2001) Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulumtargeted Bcl-2 is protective against Bax-induced cell death. J. Biol. Chem. 276, 44117-44128
18. Kang, C. B., Tai, J., Chia, J., and Yoon, H. S. (2005) The flexible loop of Bcl-2 is required for molecular interaction with immunosuppressant FK-506 binding protein 38 (FKBP38). FEBS Lett. 579, 1469-1476
19. Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., Roberts, L., Tahir, S. K., Xiao, Y., Yang, X., Zhang, H., Fesik, S., Rosenberg, S. H., and Elmore, S. W. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428
20. Sakai, Y., Goodison, S., Kusmartsev, S., Fletcher, B., Eruslanov, E., Cao, W., Porvasnik, S., Namiki, K., Anai, S., and Rosser, C. J. (2009) Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. Prostate 69, 459-470